ArticleBMC microbiology2026
Analysis of nontuberculous mycobacteria laboratory detection data from a designated hospital in Henan Province, China.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNontuberculous mycobacteria (NTM) infections are emerging globally, yet epidemiological data from central China remain limited. This study analyzed mycobacterial culture and identification data from Henan Provincial Chest Hospital (2020–2024) to assess NTM detection patterns and species distribution.
methodsThis retrospective laboratory surveillance study analyzed mycobacterial culture and species identification data from Henan Provincial Chest Hospital (January 2020–December 2024). Cultures were performed using the MGIT system with MPB64 antigen detection for MTBC and PNB growth for presumptive NTM identification. Species identification employed DNA microarray targeting the 16–23 S rRNA internal transcribed spacer region. Clinical data (symptoms, radiology, comorbidities), repeated cultures per ATS guidelines, and treatment outcomes were not available. GeneXpert MTB/RIF-negative cases with cycle threshold less than 42 from 2022 to 2024 were analyzed retrospectively.
resultsAmong 6,939 culture-positive specimens, 962 (13.86%) were identified as NTM, with annual isolation rates increasing from 10.76% to 16.37%. Of these 962 NTM cases, 532 isolates (55.3%) underwent DNA microarray species identification, revealing M. intracellulare as predominant (79.51%, 423/532), followed by M. abscessus complex (10.53%, 56/532), M. kansasii (4.32%, 23/532), M. avium (3.01%, 16/532), and M. fortuitum (1.69%, 9/532). Among 532 NTM isolates undergoing species identification, males (59.77%) and elderly patients (> 60 years) predominated. In a subgroup of 230 patients with GeneXpert MTB/RIF-negative results but cycle threshold (Ct) values < 42, 101 were identified as NTM-positive. Notably, 94.25% of these cases were attributed to the Mycobacterium avium complex (MAC), with 93 showing low Ct for probe A and 7 for probe C.
conclusionsNTM isolation rates are rising in Henan Province, with M. intracellulare as the predominant species. GeneXpert-negative cases with low Ct values for probe A may benefit from supplementary acid-fast staining and species identification to enhance early NTM detection, findings represent laboratory detection patterns from single specimens and cannot distinguish colonization from clinically significant disease per ATS/IDSA diagnostic criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.